Introduction
Antiretroviral therapy (ART) suppresses viral replication in most HIV-infected individuals with a substantial impact on morbidity and mortality [1] . However, ART does not eradicate latently infected cells [2] , and plasma viremia rebounds after treatment is interrupted [3] . Starting ART during the earliest stages of HIV infection is associated with a smaller HIV reservoir [4] , reduced cellular HIV transcription [5] , and preserved immune response [6] . A delayed viral rebound has been observed for variable periods of follow-up (generally 6 up to 48 months) in a small proportion of individuals after cessation of ART initiated during the earliest phases of HIV infection [7] [8] [9] . However, studies with longer follow-up (18 months up to several years) showed that virus control was not maintained in most individuals after early ART interruption [10] [11] [12] [13] [14] . In 2010, the French 'Virological and Immunological Studies in Controllers after Treatment Interruption' (VISCONTI) group reported a selected subset of individuals in whom HIV-RNA remained below 50 copies/ml for several years after the interruption of prolonged ART that was initiated during primary HIV infection (median duration 75 months) [15] . The same group calculated that the probability of maintaining viral control at 24 months post early treatment interruption could be as high as 15%, which is much higher than observed in persons who exhibit spontaneous control, without ART. This study has revived considerable interest in using early and prolonged ART to achieve long-term infection control and may have important implications in the search for a functional HIV cure. Similar follow-up studies with a larger number of individuals [16] [17] [18] [19] confirmed the existence of posttreatment controllers at a lower frequency below 10%.
Here, we performed a retrospective analysis including clinical and virologic data collected from participants of the San Diego Primary Infection Cohort (SD PIC) over 18 years of follow-up. Our objective was to find posttreatment controllers among those participants who interrupted ART after being virologically suppressed.
Methods and results
Since 1996, the SD PIC has enrolled 616 individuals diagnosed during acute and very early HIV infection and followed for several years into chronic infection. The estimated date of HIV infection (EDI) is determined for each individual using established algorithms [20] . Importantly, the duration of HIV infection at the time ART was started was calculated differently for our cohort compared with the VISCONTI group. We calculated the interval between EDI (as described in [20] ) and start of ART, whereas the French group used time from documented primary HIV infection (defined as the date of a negative/incomplete HIV-1 western blot and a positive p24 Ag test, or a positive HIVantibody test with a negative one within the previous 3 months). This corresponds to a difference of 3-5 weeks between our two estimates of ART start. For the purpose of this analysis, we added 4 weeks to our EDI (referred to 'adjusted EDI' in the text).
We used the following inclusion criteria for this retrospective analysis of SD PIC participants: ART start within 16 weeks (i.e. 4 months) from the 'adjusted EDI' (n ¼ 235, 38%); reached suppressed HIV-RNA levels (<50 or <400 copies/ml depending on sensitivity of the assay used) within 36 weeks of ART initiation (n ¼ 116, 50%); maintained suppressed HIV-RNA for at least 24 weeks, with one blip less than 200 copies/ml allowed (n ¼ 109, 94%); and documented treatment interruption (for any reason other than virologic failure) (n ¼ 16, 15%). If exact information about timing of ART interruption was missing, a manual review of clinical charts was performed and individuals were excluded from this analysis if the ART interruption date was not appropriately documented.
In our cohort, we were able to identify 109 individuals who started ART within 16 weeks from our 'adjusted EDI' and subsequently achieved suppressed HIV-RNA in blood plasma (median time from ART initiation to HIV-RNA suppression was 16 weeks), and remained suppressed for at least 24 weeks. Sixteen had a documented episode of voluntary ART interruption (see Figure S1 for selection criteria, http://links.lww.com/QAD/A757). Table 1 summarizes the main characteristics of the 16 individuals who did interrupt ART (supplemental Table 1 shows individual characteristics, http://links.lww.com/QAD/A757). Half of the study participants started ART within 8.6 weeks from adjusted EDI and were treated for 1.75 years before ART interruption.
None of the SD PIC participants who met the described criteria for inclusion [0%, 95% confidence interval (CI): 0-14.3%] demonstrated sustained control of HIV after interruption of their ART. This estimate was not statistically different from the VISCONTI estimate (15.6%, CI: 5.3-32.8%, Fisher exact P ¼ 0.15).
In fact, 100% of participants who stopped ART had detectable HIV-RNA within a median of 29 days (0.9 months) from ART interruption (range 6-197 days), see Fig. 1 . None of the tested variables (inclusive baseline and peak HIV-RNA viral load, baseline and nadir CD4 þ cell count, timing of ART initiation, and time on ART) was associated with longer time to viral rebound. However, our analysis was limited because of the retrospective study design and the imprecise time to rebound estimates because of sparse sampling.
Discussion
The recent report of the VISCONTI posttreatment controllers sparked considerable interest among the HIV community. The 15% prevalence of posttreatment controllers in the VISCONTI study is much higher than both the previous reports in similar populations and observations of spontaneous viral control in natural history studies. In our cohort of 109 recently HIVinfected individuals who initiated ART within 16 weeks of their EDI and achieved sustained virologic control for a median of 1.75 years, we were able to find 16 individuals who interrupted therapy whereas their HIV-RNA viral load was undetectable in blood plasma (<50-400 copies/ ml). All of them rebounded to detectable HIV-RNA levels by the following visit, achieving an average of 3.5 log 10 HIV-RNA copies/ml within 6-197 days from ART interruption. Of note, because of the small sample size, we obtained large CIs around our negative result (0-14.3%), which are overlapping with the CIs reported by the VISCONTI group (5.3-32.8%), and therefore we were not able to detect a significant difference from the reported VISCONTI group. A similar analysis performed among participants of the Seattle primary infection cohort found 22 individuals who interrupted ART (out of 389) and only one was able to control viral load to levels below 500 copies/ml for at least 24 months [21] . Based on our data, we calculated that a sample size of 34 (or 54) individuals interrupting ART would have been necessary to detect a statistically significant difference between 0% and the VISCONTI proportion of 15% posttreatment controllers with a 76% power (or 90% power, respectively), using a Fisher exact test with a ¼ 0.05.
The not significantly different frequency of posttreatment control between the VISCONTI and SD PIC cohort (15 versus 0%) could have several explanations. Most importantly, all of the SD PIC participants started ART later compared with the VISCONTI cohort (median of 8.6 weeks compared with 2.3 and 5.8 weeks for VISCONTI controller and noncontroller, respectively) and also had a shorter duration on ART (2.0 years compared with 5 years for the VISCONTI controllers). [22, 23] ) is similar or less compared with the prevalence reported in the VISCONTI cohort (29%) and in the Seattle primary infection cohort (33%) [21] . This might be a consequence of more severe seroconversion symptoms reported in people carrying HLA risk alleles, making them more likely to be identified during primary infection.
VISCONTI posttreatment controllers also had a very small HIV-DNA reservoir [19] , confirming that the initiation of early ART decreases the pool of latently infected cells [4] . However, a small reservoir alone does not explain why these participants did not experience viral rebound after ART interruption as reemergence of plasma HIV-RNA in HIV-infected individuals treated early and who have small reservoirs has been repeatedly reported [10] [11] [12] [13] [14] . One interesting characteristic of the VISCONTI cohort is the relatively small contribution of long-lived central memory T cells to the HIV reservoir compared with the previous reports [24] . This suggests that perhaps the distribution of the viral reservoir may play an important role in controlling infection in the absence of ART. Future studies are needed to confirm the VISCONTI findings and to further explore the mechanisms of posttreatment control.
